抗人CD19单克隆抗体(克隆号FMC63) ，体内实验级重组，小鼠IgG2a Kappa | Syd Labs PA007271.m2a
悉得（Syd Labs）体内实验级重组抗人CD19单克隆抗体，小鼠IgG2a Kappa（克隆号FMC63，货号：PA007271.m2a），纯度>95%，适用于体外和体内研究。其不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
- 产品参数
- 文献
- More Offers
| 货号 | PA007271.m2a |
|---|---|
| 产品名称 | 抗人CD19单克隆抗体(克隆号FMC63) ，体内实验级重组，小鼠IgG2a Kappa | Syd Labs PA007271.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody（Clone FMC63）,Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | 悉得（Syd Labs） |
| 别称 | B 淋巴细胞抗原 CD19，分化簇 19，B 淋巴细胞表面抗原 B4，T 细胞表面抗原 Leu-12，CVID3 |
| 概述 | 悉得（Syd Labs）提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | FMC63 |
| 同种型 | 小鼠 IgG2a Kappa |
| 应用 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人 CD19蛋白影响的生物学途径的测定。 |
| 免疫源 | 抗人 CD19单克隆抗体(克隆号: FMC63)是用哺乳动物细胞生产的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD19单克隆抗体(克隆号FMC63)，小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存3个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007271.m2a 悉得（Syd Labs）提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | 悉得（Syd Labs）在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系悉得（Syd Labs）中国代理商。 关于悉得（Syd Labs）产品如果有任何技术或其它问题，欢迎随时联系悉得（Syd Labs）国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
描述
了解更多抗人CD19单克隆抗体（clone：FMC63）引用文献，请查看：抗人CD19单抗（克隆号FMC63）引用文献
抗人CD19抗体（FMC63）参考文献:
1. CD19 CAR antigen engagement mechanisms and affinity tuning
Changhao He,et al.Sci Immunol. 2023.PMCID: PMC10228544
“Chimeric antigen receptor (CAR) T cell therapy relies on T cells that are guided by synthetic receptors to target and lyse cancer cells. CARs bind to cell surface antigens through a scFv (binder), the affinity of which is central to determining CAR T cell function and therapeutic success. CAR T cells targeting CD19 were the first to achieve dramatic clinical responses in patients with relapsed/refractory B cell malignancies and to be approved by the U.S. Food and Drug Administration (FDA). We report cryo-EM structures of CD19 antigen with the binder FMC63 which is used in four FDA-approved CAR T cell therapies (Kymriah, Yescarta, Tecartus, Breyanzi), and the binder SJ25C1 which has also been used extensively in multiple clinical trials. We use these structures for molecular dynamics simulations which guide creation of lower or higher affinity binders, and ultimately produce CAR T cells endowed with distinct tumor recognition sensitivities. The CAR T cells exhibit different antigen density requirements to trigger cytolysis and differ in their propensity to prompt trogocytosis upon contacting tumor cells. Our work shows how structural information can be applied to tune CAR T cell performance to specific target antigen densities.”
2. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
Yunlin Zhang,et al.Mol Cancer. 2023.PMCID: PMC10709913
“Background：Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contribute to this failure, including CD19-negative escape and CAR T dysfunction. All four commercial CART19 products utilize the FMC63 single-chain variable fragment (scFv) specific to a CD19 membrane-distal epitope and characterized by slow association (on) and dissociation (off) rates. We hypothesized that a novel anti-CD19 scFv that engages an alternative CD19 membrane-proximal epitope independent of FMC63 and that is characterized by faster on- and off-rates could mitigate CART19 failure and improve clinical efficacy.Methods：We developed an autologous CART19 product with 4-1BB co-stimulation using a novel humanized chicken antibody (h1218). This antibody is specific to a membrane-proximal CD19 epitope and harbors faster on/off rates compared to FMC63. We tested h1218-CART19 in vitro and in vivo using FMC63-CART19-resistant models. We conducted a first-in-human multi-center phase I clinical trial to test AT101 (clinical-grade h1218-CART19) in patients with relapsed or refractory (r/r) NHL.Results：Preclinically, h1218- but not FMC63-CART19 were able to effectively eradicate lymphomas expressing CD19 point mutations (L174V and R163L) or co-expressing FMC63-CAR19 as found in patients relapsing after FMC63-CART19. Furthermore, h1218-CART19 exhibited enhanced killing of B-cell malignancies in vitro and in vivo compared with FMC63-CART19. Mechanistically, we found that h1218-CART19 had reduced activation-induced cell death (AICD) and enhanced expansion compared to FMC63-CART19 owing to faster on- and off-rates. Based on these preclinical results, we performed a phase I dose-escalation trial, testing three dose levels (DL) of AT101 (the GMP version of h1218) using a 3 + 3 design. In 12 treated patients (7 DLBCL, 3 FL, 1 MCL, and 1 MZL), AT101 showed a promising safety profile with 8.3% grade 3 CRS (n = 1) and 8.3% grade 4 ICANS (n = 1). In the whole cohort, the overall response rate was 91.7%, with a complete response rate of 75.0%, which improved to 100% in DL-2 and -3. AT101 expansion correlates with CR and B-cell aplasia.Conclusions：We developed a novel, safe, and potent CART19 product that recognizes a membrane-proximal domain of CD19 with fast on- and off-rates and showed significant efficacy and promising safety in patients with relapsed B-cell NHL.”
3. Solving the mystery of the FMC63-CD19 affinity
Jacqueline Seigner,et al.Sci Rep. 2023.PMCID: PMC10754921
“The majority of approved CAR T cell products are based on the FMC63-scFv directed against CD19. Surprisingly, although antigen binding affinity is a major determinant for CAR function, the affinity of the benchmark FMC63-scFv has not been unambiguously determined. That is, a wide range of affinities have been reported in literature, differing by more than 100-fold. Using a range of techniques, we demonstrate that suboptimal experimental designs can cause artefacts that lead to over- or underestimation of the affinity. To minimize these artefacts, we performed SPR with strictly monomeric and correctly folded soluble CD19, yielding an FMC63-scFv affinity of 2–6 nM. Together, apart from analyzing the FMC63-scFv affinity under optimized conditions, we also provide potential explanations for the wide range of published affinities. We expect that this study will be highly valuable for interpretations of CAR affinity-function relationships, as well as for the design of future CAR T cell generations.”
Syd Labs抗人CD19单克隆抗体(克隆号FMC63)，小鼠IgG2a Kappa （货号：PA007271.m2a）推荐同型对照抗体:
重组小鼠IgG2a同型对照抗体，体内实验级（In Vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody）
Syd Labs提供以下体内实验级重组抗人CD19抗体:
抗人CD19单克隆抗体(克隆号: SJ25c1)（Anti-human CD19 monoclonal antibody (Clone: SJ25C1)）
抗人CD19单克隆抗体(克隆号: B43)（Anti-human CD19 monoclonal antibody (Clone: B43)）
抗人CD19单克隆抗体(克隆号: FMC63)（Anti-human CD19 monoclonal antibody (Clone: FMC63)）
Syd Labs提供以下体内实验级重组抗小鼠CD19抗体:
抗小鼠 CD19单克隆抗体(克隆号: 1D3)（Anti-mouse CD19 monoclonal antibody (Clone: 1D3)）
Syd Labs提供以下流式细胞术用重组抗人CD19抗体:
Syd Labs提供以下流式细胞术用重组抗小鼠CD19抗体:
流式细胞术用抗小鼠 CD19单克隆抗体(克隆号: 1D3)（Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry）
请记住我们的产品信息:体内实验级重组抗人CD19单克隆抗体(克隆号FMC63)，小鼠IgG2a Kappa: PA007271.m2a Syd Labs In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: FMC63), Mouse IgG2a Kappa。